Tumor mutations may not predict response to immunotherapy, study finds

The number of mutations in the DNA of cancerous tumors may not be an indicator of how well patients will respond to immune checkpoint inhibitors (ICIs), a commonly prescribed type of immunotherapy, a team led by UT Southwestern Medical Center researchers reported in a retrospective study.

Related Keywords

David Hsieh , Maishara Muquith , Ut Southwestern Medical Center , Caris Precision Oncology Alliance , Drug Administration , Caris , Haroldc Simmons Comprehensive Cancer Center , Division Of Hematology , Nature Cancer , Medical Center , Assistant Professor , Internal Medicine , Comprehensive Cancer Center ,